Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
GSK opens new site in UK unlike rival AstraZeneca
08:22am, Thursday, 14'th Sep 2023
GSK has opened a new £65 million drug factory in Hertfordshire in a move it said would enable rapid production of medicines developed through its research pipeline. In contrast to UK rival AstraZenec
AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo
12:50pm, Tuesday, 12'th Sep 2023
Data from a late-stage study shows that AstraZeneca's (AZN) Tagrisso combined with chemotherapy cut the risk of disease progression or death by 38% in certain lung cancer patients.
AstraZeneca bounces back from reports that CEO Soriot is eyeing exit
08:47am, Tuesday, 12'th Sep 2023
Shares in AstraZeneca PLC (LSE:AZN) have bounced back after falling on a report that chief executive Pascal Soriot is looking to step down, possibly as soon as next year. Following a steep 4.1% dro
AstraZeneca's Tagrisso-chemo combo results raise bar for J&J cancer drug-analysts
08:15am, Monday, 11'th Sep 2023
Data released on Monday by AstraZeneca from a late-stage trial combining its blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer raises the bar for Johnson & Johnson's ri
AstraZeneca (AZN) Gets FDA CRL for Ultomiris in New Indication
11:18am, Wednesday, 06'th Sep 2023
AstraZeneca (AZN) said the CRL for Ultomiris for NMOSD indication does not raise any concerns about the efficacy and safety data from the study.
AstraZeneca and Alexion working with FDA on US label expansion for Ultomiris
02:51am, Wednesday, 06'th Sep 2023
AstraZeneca PLC (LSE:AZN) said the US Food and Drug Administration (FDA) has responded to a request to expand the use of the drug Ultomiris by asking for a risk evaluation and mitigation strategy. In
Here is What to Know Beyond Why AstraZeneca PLC (AZN) is a Trending Stock
10:31am, Monday, 04'th Sep 2023
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?
06:15am, Saturday, 02'nd Sep 2023
Veracyte's revenue sharply rose in the second quarter. The company is moving toward profitability.
More AstraZeneca drugs to be added to US IRA list, Barclays predicts
08:01am, Thursday, 31'st Aug 2023
AstraZeneca PLC (LSE:AZN) faces several negative headwinds for US sales of some of its drugs from the new Inflation Reduction Act's rules on negotiated price cuts, according to Barclays, with a less
Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)
04:31am, Thursday, 31'st Aug 2023
The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.
Cantor's Louise Chen breaks down new Medicare drug pricing negotiations
03:02pm, Tuesday, 29'th Aug 2023
Louise Chen, Cantor Fitzgerald, joins 'Power Lunch' to discuss Medicare drug priced ahead of Biden's news conference on the negotiations.
Oncology Market's Huge Potential Puts These Stocks in Focus
09:46am, Monday, 28'th Aug 2023
The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meanin
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
01:38pm, Friday, 25'th Aug 2023
Rare disease stocks have a difficult task. The rarer a disease is, the less public research goes into studying it.
AstraZeneca's (AZN) Lynparza Gets Expanded Use Nod in Japan
01:32pm, Friday, 25'th Aug 2023
AstraZeneca (AZN) gets approval for Lynparza with abiraterone and prednisolone combo in Japan to treat adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.
AstraZeneca files lawsuit against U.S. over drug pricing
11:44am, Friday, 25'th Aug 2023
Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the lawsuit filed by AstraZeneca (AZN) joining Johnson & Johnson (JNJ), Merck (MRK), and Bristol-Myers (BMY) in a lawsuit against the U.
